Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Clinical trial NCT05398809 · RECRUITING

Trial details

NCT number: NCT05398809
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Start date: 2023-01-18
Primary completion: 2027-12-01
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.